Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt

The market is likely to separate operating quality from headline noise here. What matters is that the legacy patent-cliff drag is still being offset by new launches, which supports the thesis that the portfolio transition is intact rather than broken. That keeps the stock in a “prove-it” range: if investors believe the newer brands can keep compounding, NVS deserves to hold a premium multiple versus slower-growth large pharma; if not, the declining mix will keep compressing margins.

The bigger second-order issue is capital allocation. The balance sheet deterioration is not a solvency story, but it does mean future EPS growth is more dependent on operating delivery because buyback support can’t be pushed as aggressively once financing costs and acquisition spending rise. In credit, the move should be mostly shrugged off: the rating profile still screens as high-grade, so spreads are more likely to stay rangebound unless leverage keeps climbing without corresponding pipeline conversion.

Contrarian view: consensus may be too focused on the reported earnings softness and not enough on the duration extension and launch optionality embedded in oncology/immunology. The underappreciated risk is that gross-margin erosion becomes structural if legacy volume decays faster than the newer assets scale, which would cap re-rating even with headline revenue growth. The thesis is falsified if the next quarterly update shows launch deceleration, further gross margin slippage, or management signals that H2 growth is being pulled forward rather than sustained.